PMID: 6159812Sep 1, 1980Paper

Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma

Annals of Internal Medicine
J U GuttermanS Pestka

Abstract

Thirty-eight patients with advanced breast cancer, multiple myeloma, and malignant lymphoma were treated with partially purified (about 0.1%) leukocyte interferon. Patients were treated with a remission-induction schedule of 3 million to 9 million antiviral units daily intramuscularly for 4 to 26 weeks. Responding patients were maintained on a schedule of 3 million U three times weekly. Tumor regression was observed in seven of 17 patients with breast cancer. Six of 10 patients with multiple myeloma responded with a decrease of at least 50% in serum myeloma protein levels or Bence Jones protein excretion. Six of the 11 lymphoma patients achieved tumor regression. Complete remissions occurred in two patients. Of the 19 responding patients, five remain on study for 52 to 63 weeks. Toxicity included low-grade fever, fatigue, anorexia, and partial alopecia. Myelosuppression (lowest median leukocyte count, 2500/mm3; granulocytes, 1300/mm3) occurred in most patients. On the basis of this pilot study, we conclude that leukocyte interferon can induce tumor regression in patients with advanced cancer.

Citations

Oct 1, 1992·American Journal of Hematology·N M Chowhan, M H Zarrabi
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·J WagstaffD Crowther
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·K EzakiJ Inagaki
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·S E Krown
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·U Elsässer-BeileE Schöpf
Jan 1, 1984·Cancer Chemotherapy and Pharmacology·U BruntschW M Gallmeier
Sep 1, 1995·Medical Oncology·F B Hagemeister
Jan 1, 1984·Neurosurgical Review·M Nagai, T Arai
Sep 1, 1990·Breast Cancer Research and Treatment·D L Longo, L C Hartmann
Jan 1, 1986·Breast Cancer Research and Treatment·K A Foon
Aug 1, 1991·Breast Cancer Research and Treatment·J E MacheledtF A Holmes
Oct 15, 2009·Cancer Immunology, Immunotherapy : CII·Lance U'RenSteven Dow
Jan 1, 1981·Pharmacology & Therapeutics·V Bocci
Jan 1, 1985·Pharmacology & Therapeutics·P B Fisher, S Grant
Jan 1, 1988·Pharmacology & Therapeutics·E C Borden
Oct 1, 1993·Pharmacology & Therapeutics·P Fitzgerald-Bocarsly
Jan 1, 1996·Pharmacology & Therapeutics·J Bubenik
May 15, 2003·The Surgical Clinics of North America·Charles Komen Brown, John M Kirkwood
Jan 15, 1983·Lancet·P W TrownJ U Gutterman
May 7, 1999·International Journal of Immunopharmacology·J W Hadden
Jan 1, 1984·Critical Reviews in Oncology/hematology·R V Smalley, R K Oldham
Jan 5, 1984·The New England Journal of Medicine·J R QuesadaJ U Gutterman
Nov 1, 1984·The New England Journal of Medicine·K A FoonJ Zeffren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.